|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
intravenous infusion
subcutaneous injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
2015
|
|
gptkbp:ATCCode
|
L01XC24
|
|
gptkbp:brand
|
gptkb:Darzalex_Faspro
gptkb:Darzalex
|
|
gptkbp:canInterfereWith
|
blood compatibility testing
indirect antiglobulin test
|
|
gptkbp:CASNumber
|
945721-28-8
|
|
gptkbp:combinationTherapy
|
gptkb:cyclophosphamide
gptkb:prednisone
gptkb:carfilzomib
gptkb:dexamethasone
gptkb:lenalidomide
gptkb:melphalan
gptkb:bortezomib
gptkb:pomalidomide
|
|
gptkbp:developedBy
|
gptkb:Janssen_Biotech
|
|
gptkbp:discoveredBy
|
gptkb:Genmab
|
|
gptkbp:firstBook
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
daratumumab
|
|
gptkbp:indication
|
relapsed or refractory multiple myeloma
newly diagnosed multiple myeloma
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:CD38
|
|
gptkbp:marketedIn
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
induces apoptosis of CD38-expressing cells
mediates immune effector functions
|
|
gptkbp:monitors
|
liver function tests
complete blood count
renal function tests
|
|
gptkbp:pharmacokinetics
|
half-life ~18 days
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:PubChem_CID
|
DB09331
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
fatigue
neutropenia
thrombocytopenia
infusion-related reactions
|
|
gptkbp:target
|
gptkb:CD38
|
|
gptkbp:type
|
human IgG1 kappa monoclonal antibody
|
|
gptkbp:UNII
|
82ZZY92T6T
|
|
gptkbp:usedFor
|
multiple myeloma
light chain amyloidosis
|
|
gptkbp:bfsParent
|
gptkb:Darzalex
|
|
gptkbp:bfsLayer
|
6
|